Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA012JP

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with RA who participated in Study MRA012JP.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chugai Pharmaceutical

Criteria

Inclusion criteria

• Patients must suffer from RA, and must have participated in the preceding study.

• Patients must have been confirmed to be appropriate on week 52 of the preceding study by X radiography.

Exclusion criteria

• Patients evaluated as belonging to Steinbrocker's class IV within 4 weeks before administration of the study drug

• Patients who have not been registered by 3 months after week 52 of the preceding study